Filter by: patients
Home > Community Treatment Reports and Side Effects > aprepitant Treatment Report
What is aprepitant?

Aprepitant is an antiemetic used to prevent acute and delayed nausea and vomiting associated with chemotherapy (in combination with other antiemetics); and to prevent postoperative nausea and vomiting.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Nausea 2 0
Nausea and vomiting 1 0
Treat side effects of another treatment 1 1 Efficacy_major
Abdominal pain 1 0

See all 3 patients currently taking aprepitant

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Dosages

  125 mg-80 mg monthly 125 mg-80 mg weekly 125mg as needed
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking aprepitant (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped taking aprepitant

Reported Duration See details about how long patients take this treatment ▼

Currently Taking aprepitant

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking aprepitant

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of aprepitant

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of aprepitant

Very
 0 0%
Somewhat
 0 0%
A little
 1 100%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of aprepitant

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 27, 2012.